Introduction {#S1}
============

Mitochondria are the powerhouse of the cell due to their primary contribution in cell respiration. In addition to their canonical role in cellular metabolism, mitochondria have emerged as a central platform for the regulation of antiviral signaling pathways ([@B71]). Although several pathogen-activated pathways are influenced by mitochondria, this role is to be attributed mainly to the mitochondrial localization of the signaling adaptor mitochondrial antiviral signaling (MAVS) protein, a key mediator of the innate immune response during RNA viral infection ([@B108]).

In the last years, remarkable advances have been made in our knowledge about the molecular mechanisms underlying MAVS signaling. The development of innovative technologies in the field of transcriptomics, proteomics, reverse genetics, and structural and cell biology has dramatically improved our understanding of how RNA viruses can be sensed and lead to the expression of hundreds of genes dedicated to infection inhibition. In particular, yeast two-hybrid and mass spectrometry (MS) approaches have provided detailed information on how MAVS-dependent antiviral responses are rapidly activated, and also tightly controlled by protein catabolic processes, i.e. the ubiquitin--proteasome system and autophagy, to avoid excessive inflammation and cell death. Moreover, these approaches have widened our understanding of how viral proteins are able to inhibit MAVS activation to accomplish viral replication and how energy metabolism may influence mitochondrial antiviral pathways.

Here, we review our current view of MAVS signaling, highlighting how proteomics has deepened our understanding of this pathway regulation in terms of protein--protein interactions and post-translational modifications (PTMs).

Innate Immunity and Mitochondria {#S2}
================================

The innate immune response is the first line of defense against invading pathogens that is activated following the recognition of specific entities, called pathogen-associated molecular patterns (PAMPs), through a series of receptors, termed pattern recognition receptors (PRRs). Upon detection of PAMPs, the transcription of a myriad of antiviral genes is activated, establishing a cellular antiviral state that helps cells to restrict and/or clear infection ([@B6]).

Based on their structures, locations, and functional specificities, PRRs are separated into discrete families, which include the membrane bound Toll-like receptors (TLRs), the cytosolic nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), cyclic GMP-AMP (cGAMP) synthase (cGAS), and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) ([@B45]; [@B24]; [@B96]). The activity of these PRRs has been described to be influenced at various levels by mitochondria.

The TLRs are a family of transmembrane PRRs that are activated by the binding of ligands to their C-terminal leucine-rich repeats. Ten TLRs have been identified in humans, with TLRs 1, 2, 4, 5, 6, and 10 located at the cell surface and TRLs 3, 7, 8, and 9 spanning the endosomal membrane. Plasma membrane TLRs mainly recognize microbial wall components, such as lipids, polysaccharides, and proteins, while intracellular TLRs sense pathogen nucleic acids ([@B45]). Stimulation of TLRs results in the activation of the transcription factors NF-κB and IRF3/IRF7 to induce the expression of type I interferon (IFN) genes and other inflammatory cytokines.

Mitochondria are directly involved in the regulation of TLR activity. A relevant example is represented by TLR1, TLR2, and TLR4, which were reported to enhance mitochondrial ROS generation in bacteria-infected macrophages to potentiate the antimicrobial killing ([@B117]). This effect is mediated by evolutionarily conserved signaling intermediate in Toll (ECSIT) pathways, a mitochondrial matrix protein required for mitochondrial respiratory complex I activity. Following TLR engagement, the E3 ubiquitin ligase tumor necrosis factor receptor-associated factor 6 (TRAF6) binds to a fraction of the ECSIT protein that becomes accessible on the mitochondrial surface and elicits the pro-oxidant activity of ECSIT via non-degradative ubiquitination ([@B117]). Moreover, TLR4 activation drives the formation of a complex including TRAF6, ECSIT, and transforming growth factor-β-activated kinase 1 (TAK1), which promotes TAK1 kinase activity and the activation of the NF-κB signaling ([@B118]).

The NLR family of PRRs are cytoplasmic proteins that stimulate innate immunity in response to both PAMPs, such as microbial components (e.g. peptidoglycan, viral RNA), and damage-associated molecular patterns (DAMPs), including host components (cholesterol crystals, uric acid), and environmental sources (alum, asbestos, skin irritants) ([@B24]). Upon activation, a unique feature of NLRs is the formation of a multiprotein complex termed "inflammasome." Here, the NLRs bind pro-caspase-1 through the adaptor apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (CARD) (ASC). Inflammasome assembly triggers auto-catalysis of pro-caspase-1, which is able to process the pro-IL (interleukin)-1β and pro-IL-18 into their active forms in order to induce, once secreted, a broad inflammatory response ([@B90]).

A direct link between mitochondria and NLR activation has been reported for NLRP3. Active NLRP3 translocates from cytosol to mitochondria, where it functions as a scaffold for inflammasome assembly ([@B100]). Here, NLRP3 was found to interact with MAVS, with this binding being necessary for optimal inflammasome activity ([@B97]).

Cyclic GMP-AMP synthase is one of the cellular sensors of non-self DNA, together with the endosomal TLR9 and the NLR family protein Absent in Melanoma 2 (AIM2). Cytosolic DNA binds to cGAS and stimulates its enzymatic activity to form the second messenger cGAMP ([@B121]). cGAMP binds to the endoplasmic reticulum (ER) resident protein STING, promoting a conformational change that allows STING to interact with the protein kinases TBK1 (TANK binding kinase-1) and IKKs (IκB kinases) and to translocate from the ER to the Golgi apparatus. Activated TBK1 and IKKs phosphorylate the transcription factors IRF3 and NF-κB so as to induce the expression of type I IFN and inflammatory cytokines ([@B72]).

Although DNA and RNA sensing responses occur through independent receptors, the induction of the antiviral response by one of these agents also relies on the activity of the other pathway. Multiple molecular mechanisms are responsible for this strict interdependence, including the direct interaction of the main regulators of these pathways at the ER--mitochondria contact sites, as well as the fact that many downstream factors are shared between these pathways. For a more exhaustive review of the crosstalk between RNA and DNA sensing pathways, see [@B135].

The RIG-I-Like Receptor Signaling Pathways {#S3}
==========================================

Apart from the endosome localized TLRs, the recognition of non-self RNA is mediated by the cytosolic sensors of the RLR pathway ([Figure 1](#F1){ref-type="fig"}).

![Retinoic acid-inducible gene I-like receptor (RLR)--mitochondrial antiviral signaling (MAVS) protein signaling. Following viral RNA sensing, retinoic acid-inducible gene I (RIG-I)/melanoma differentiation associated gene 5 (MDA5) oligomerize and relocalize from the cytoplasm to outer mitochondrial membrane (OMM) and mitochondria-associated membrane (MAM). RIG-I/MDA5 interaction with MAVS induces MAVS oligomerization and the formation of a signalosome where the tumor necrosis factor receptor-associated factor (TRAF) proteins are recruited. TRAF proteins trigger two molecular cascades leading to: (i) IRF3 and IRF7 phosphorylation by TANK binding kinase-1 (TBK1) and IκB kinase ε (IKKε) to induce the expression of type I and type III interferons (IFNs) and (ii) NF-κB phosphorylation by the IKK α/β/γ complex to upregulate the expression of inflammatory cytokines. TIM: TRAF-interacting motif. PRR: proline-rich region. ER: endoplasmic reticulum.](fcell-08-00008-g001){#F1}

The RLR family contains three members: RIG-I, melanoma differentiation associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). All RLRs are characterized by a central DEAD box helicase/ATPase domain and a C-terminal regulatory domain (CTD), necessary for RNA binding and to prevent constitutive activation ([@B105]).

Moreover, RIG-I and MDA5 possess two N-terminal CARDs that mediate their oligomerization following RNA binding and are required for the activation of the downstream adaptor protein MAVS ([@B5]). RIG-I and MDA5 play non-redundant roles by detecting largely distinct groups of viruses and by recognizing distinct features of viral RNAs. RIG-I preferentially detects 5′-di-/triphosphorylated RNA sequences rich in poly-U or poly-UC tracts, whereas MDA5 binds to high-molecular-weight viral RNAs ([@B44]). LGP2 exhibits 30--40% amino acid sequence identity to RIG-I and MDA5, but it lacks the CARDs ([@B130]). The exact role of LGP2 in innate immunity remains not completely understood, since it has been reported to act both as a positive ([@B109]; [@B88]) and as a negative ([@B46]; [@B82]) regulator of the RLR pathway. To explain these discrepancies, it has been recently proposed that LGP2 may function as a concentration-dependent switch. Early during infection, low levels of LGP2 enhance RLR-mediated antiviral signaling, while, at later stages, IFNs stimulate the expression of LGP2, which, at high concentration, inhibits RLRs, contributing to the termination of the antiviral response ([@B8]).

The adaptor protein MAVS (also known as IPS-1/VISA/Cardif) is essential to drive innate immunity in response to RNA virus infection ([Figure 1](#F1){ref-type="fig"}). MAVS is comprised of three functional domains, a CARD at the N terminus, a proline-rich domain, and a C-terminal membrane-targeting transmembrane domain. MAVS contains three TRAF-interacting motifs (TIMs), two in the proline-rich region and one near the transmembrane domain ([@B89]; [@B108]). Through its C-terminal transmembrane domain, MAVS is anchored to different subcellular districts, including the outer mitochondrial membrane (OMM), peroxisomes, and a subdomain of the ER called the mitochondria-associated membrane (MAM) ([@B89]; [@B20]; [@B35]). It has been proposed that the differential localization of MAVS may drive distinct antiviral signaling responses, with the mitochondrial protein promoting type I IFN expression, while the peroxisomal protein signals for the induction of the type III IFN ([@B76]). Other evidence supports the involvement of peroxisomal MAVS in the early induction of IFN-stimulated genes (ISGs), before mitochondrial MAVS establishes a sustained antiviral response ([@B20]). Anyhow, these organelles are tightly connected, and mitochondria and peroxisomes interact with each other in signaling "synapses" during activation of the RIG-I pathway ([@B35]). Moreover, the different localization could also be related to the ability of MAVS to regulate other processes, as in the case of MAM, where MAVS can interact with regulators of cellular metabolism and apoptotic program ([@B31]).

Mitochondrial antiviral signaling-dependent antiviral signaling initiates after RIG-I and MDA5 sense viral RNA in infected cells ([Figure 1](#F1){ref-type="fig"}). In the absence of viral RNA, the CARDs of RIG-I/MDA5 are masked by intramolecular interactions with the helicase domain, but upon viral RNA binding, an ATP-mediated conformational change allows the formation of oligomers, which properly expose their CARDs so as to interact with the equivalent domain of MAVS ([@B48]). Moreover, RIG-I oligomers form a complex with 14-3-3ε, a mitochondria-targeting chaperone that mediates their translocation from the cytoplasm to OMM and MAM, where MAVS is localized ([@B60]). The association of RIG-I/MDA5 with MAVS triggers the formation of detergent-insoluble aggregates on the surface of mitochondria ([@B106]). This conformation is the active state of MAVS, necessary for recruiting the downstream effectors TRAF3, TRAF6, TRAF2, and TRAF5 in order to form a signaling supramolecular complex defined as the "MAVS signalosome" ([Figure 1](#F1){ref-type="fig"}) ([@B37]).

Interestingly, the spontaneous aggregation of MAVS in the absence of viral RNA is prevented by multiple N-terminal truncated proteins that are encoded by the MAVS transcript ([@B83]). In addition, the inhibition of the short MAVS proteins also results in the autophagic degradation of the full-length protein, highlighting a role of these isoforms in the control of MAVS stability in resting conditions ([@B7]).

Once recruited to the MAVS signalosome, TRAF proteins stimulate two molecular cascades leading to: (a) the phosphorylation of the transcription factors IRF3 and IRF7 by TBK1 and IKKε to induce the expression of type I/III IFNs and (b) the phosphorylation of the transcription factor NF-κB by the IKKα/β/γ complex to upregulate the expression of inflammatory genes ([@B62]). In turn, type I/III IFNs induce the expression of hundreds of ISGs to establish a protective state, eventually providing viral clearance of the infected cells, while inflammatory cytokines are mainly responsible for regulating the activity of innate and adaptive immune cells ([@B50]; [@B101]).

Regulation of Mavs Signaling by Post-Translational Modifications {#S4}
================================================================

Mass spectrometry-based analyses combined to site-specific mutagenesis approaches have greatly contributed to understand how PTM controls MAVS antiviral response ([Figure 2](#F2){ref-type="fig"}). This has been possible thanks to the improvement of methodologies for PTM enrichment and liquid chromatography-tandem MS (LC-MS/MS)-mediated detection ([@B129]). These proteomic studies allowed the identification of hundreds of modification sites in MAVS signaling proteins, whose role in the antiviral response has been extensively investigated, as described hereafter in detail.

![Regulation of RLR--MAVS signaling by post-translational modification (PTM). **(A)** RLR oligomerization is regulated by different E3 ligases that catalyze lysine 63 (K63)-linked ubiquitination (K63) of both RIG-I and MDA5 to promote oligomerization. K63-linked ubiquitination is countered by different DUBs (USPs, CYLD). K48- or K27-linked ubiquitination directs RIG-I/MDA5 to proteasomal degradation. USP and sumoylation inhibit K48-linked ubiquitination and RLR degradation. Phosphorylation levels regulated by the indicated kinases and phosphatases also regulate RIG/MDA5 oligomerization. **(B)** MAVS activity is tightly regulated by K63-linked ubiquitination of MAVS, promoting its oligomerization, and K48-linked ubiquitination, which triggers protein degradation. K48-linked ubiquitination is primed by NEMO-like kinase (NLK) and countered by ovarian tumor family deubiquitinase 4 (OTUD4) (upper panel); K27/K29-linked ubiquitination mediates NDP52-dependent autophagic degradation of MAVS (lower panel). **(C)** MAVS interaction with downstream effectors is regulated by non-degradative ubiquitination (K27- or K63-linked) and phosphorylation, as indicated.](fcell-08-00008-g002){#F2}

The main PTM responsible for the regulation of RIG-I, MDA5, and MAVS activity is ubiquitination, which acts as either a degradative or regulatory signal, depending on the type of polyubiquitin chain that is formed ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

###### 

MAVS post-translational modifications.

  Modified amino acids                      Methods                 Effects of modification on MAVS                                                             References
  ----------------------------------------- ----------------------- ------------------------------------------------------------------------------------------- ------------
  ***Phosphorylation***                                                                                                                                         
  S328/S330                                 MS/MS and mutagenesis   Activation of IRF3/7 and NF-κB.                                                             [@B43]
  Y9                                        Mutagenesis             Recruitment of TRAF3 and TRAF6 to MAVS                                                      [@B93]
  Y11/Y30/Y71                               Mutagenesis             Inhibition of MAVS--LC3 interaction to prevent autophagy-mediated MAVS degradation          [@B12]
  T234/S233                                 Mutagenesis             Recruitment of PLK1 to inhibit MAVS activation                                              [@B110]
  S442                                      MS/MS and mutagenesis   Mediated by TBK1 and IKK to recruit IRF3 binding and activation                             [@B61]
  S121/S212/S258/S329                       MS/MS and mutagenesis   Phosphorylation of MAVS by NLK causes its degradation                                       [@B52]
  ***Ubiquitination***                                                                                                                                          
  K7/K500                                   Mutagenesis             K48-linked ubiquitination by MARCH5 to promote MAVS proteasomal degradation                 [@B131]
  K7/K10                                    MS/MS and mutagenesis   K48-linked ubiquitination by TRIM25 to promote MAVS proteasomal degradation                 [@B9]
  K7                                        Mutagenesis             K27-linked ubiquitination by MARCH8 for NDP52-dependent autophagic degradation of MAVS      [@B41]
  K362/K461                                 Mutagenesis             K48-linked ubiquitination by RNF5 for MAVS proteasomal degradation                          [@B140]
  K10/K311/K461                             Mutagenesis             K63-linked polyubiquitination by TRIM31 to promote the aggregation and activation of MAVS   [@B57]
  K371/K420                                 Mutagenesis             K48-linked ubiquitination by AIP4 for MAVS proteasomal degradation                          [@B134]
  K420                                      Mutagenesis             K48-linked ubiquitination by pVHL for proteasomal degradation of MAVS                       [@B21]
  K371/K420/K500                            MS/MS and mutagenesis   K11-linked ubiquitination by TRIM29 for proteasomal degradation of MAVS                     [@B124]
  K325                                      Mutagenesis             K27-linked polyubiquitination by TRIM21 to promote association with TBK1                    [@B126]
  K297/K311/K348 and K362                   MS/MS and mutagenesis   K27-/K29-linked polyubiquitination by RNF34 for NDP52-dependent autophagic degradation      [@B33]
  ***O-GlcNAcylation***                                                                                                                                         
  S366                                      MS/MS and mutagenesis   Promotes K63-linked ubiquitination of MAVS                                                  [@B54]
  T321/S324/T328/S329/S300/S338/T342/S347   MS/MS and mutagenesis   Promotes K63-linked ubiquitination of MAVS                                                  [@B94]

MAVS, mitochondrial antiviral signaling protein; MS, mass spectrometry; TRAF, tumor necrosis factor receptor-associated factor; PLK1, Polo-like kinase 1; TBK1, TANK binding kinase-1; IKK, IκB kinase; NLK, NEMO-like kinase.

RIG-I/MDA5 Ubiquitination {#S4.SS1}
-------------------------

A series of E3 ubiquitin ligases catalyzing non-degradative lysine 63 (K63)-linked ubiquitination, including TRIM25, RIPLET, TRIM4, and MEX3C, were reported to induce MAVS activity by triggering ubiquitin-dependent RIG-I tetramerization through their CARDs ([@B77]). Interestingly, both covalently linked and unanchored ubiquitin chains were shown to promote RIG-I oligomerization. Unexpectedly, the same E3 ligase was reported to mediate either one or the other type of ubiquitination in independent studies ([@B80]; [@B40]). An explanation for these discrepant results was recently proposed by a co-immunoprecipitation (coIP)/MS-based proteomic study that revealed how the E3 ligase RIPLET can indeed mediate both types of ubiquitination depending on which type of E2 ubiquitin-conjugating enzyme has been bound (i.e. Ube2D3 for covalently linked ubiquitination, Ube2N for unanchored ubiquitination) ([@B91]). LC-MS/MS analyses have also contributed to identifying lysine residues 48, 96, and 172 in the CARDs of RIG-I that are ubiquitinated by RIPLET and required for MAVS activation ([@B91]).

K63-linked ubiquitination is also necessary for the oligomerization of MDA5. TRIM65 was identified by an LC-MS/MS-based interactome analysis as the E3 ligase responsible for this regulation by targeting the helicase domain of MDA5 at lysine 743 ([@B49]). Using a similar coIP/MS approach, TRIM65-mediated MDA5 ubiquitination was found to be stimulated by the interaction with the adaptor protein ARRDC4, whose expression is upregulated in infected cells ([@B69]).

Retinoic acid-inducible gene I/MDA5-mediated activation of MAVS needs to be tightly regulated in order to ensure the optimal activation and timely termination of innate antiviral response. To this aim, K63-linked ubiquitination of RIG-I and MDA5 is countered by a series of deubiquitinating enzymes (DUBs), such as USP3, USP21, and CYLD ([@B18]; [@B23]; [@B56]). Insights on how DUBs can be turned on during infection came from a study showing that CYLD activity is positively regulated by Syndecan-4 (SDC4), a proteoglycan whose expression is induced by type-I IFN. In a yeast two-hybrid screen, SDC4 was identified as a RIG-I interacting protein that promotes the binding of RIG-I with CYLD in order to decrease K63-linked ubiquitination ([@B56]).

Degradative ubiquitination also contributes to turning off the mitochondrial antiviral response by regulating the stability of RIG-I and MDA5. The E3 ligases STUB1, RNF122, RNF125, TRIM13, and TRIM40 (the first three identified by proteomic analyses) were shown to mediate lysine 27 (K27)- or lysine 48 (K48)-linked polyubiquitination of RIG-I/MDA5, which results in their proteasomal degradation ([@B2]; [@B74]; [@B115]; [@B138], [@B137]; [@B141]). How degradative ubiquitination is triggered upon RIG-I activation by non-degradative ubiquitination was investigated using an LC-MS/MS approach. This study showed that K63-linked polyubiquitination of RIG-I rapidly enhances its binding to a protein complex containing p97, UFD1, and NPL4, which in turn recruits the E3 ligase RNF125 to trigger K48-linked polyubiquitination of RIG-I and subsequent degradation ([@B29]).

Retinoic acid-inducible gene I stability is also controlled by autophagy, a catabolic process that plays an important role in the regulation of innate immune response by both degrading invading pathogens and contributing to the termination of the inflammatory response ([@B103]). The autophagic degradation of RIG-I is regulated by leucine-rich repeat containing protein 25 (LRRC25), which binds to RIG-I when it is associated to the IFN-inducible ubiquitin-like protein 15 (ISG15). This protein complex promotes the interaction between RIG-I and the autophagic cargo receptor p62, which is responsible for the selective engulfment of RIG-I by autophagosomes ([@B22]). Interestingly, during infection, this degradative mechanism is transiently counteracted by a different leucine-rich repeat containing protein, LRRC59, which binds to ISG15-associated RIG-I and inhibits the association between LRRC25 and RIG-I ([@B122]).

Conversely, degradative ubiquitination of MDA5 and RIG-I is negatively regulated by different mechanisms, such as deubiquitination, which is mediated by the DUB USP4 ([@B113]), and sumoylation, which prevents K48-linked ubiquitination of these proteins through the incorporation of the ubiquitin-like (UBL) modifier SUMO, as it was characterized by two-step immunoaffinity purification and LC-MS/MS analyses ([@B38]).

Recently, NLRP12, a protein of the NLR family, has been reported to negatively control the RLR signaling pathway by modulating both K63- and K48-linked ubiquitination of RIG-I, uncovering an important crosstalk between these innate immune receptor families. In detail, NLRP12 interacts with the ubiquitin ligase TRIM25, preventing RIG-I activation mediated by K63-linked ubiquitination, as well as with RNF125, enhancing K48-linked degradative ubiquitination of RIG-I ([@B11]). Of note, RIG-I degradation is also a mechanism by which the antiviral response is regulated by members of the lectin family, a different type of PRR that is activated by glycan PAMPs. In particular, the lectin Siglec-G (sialic-acid-binding immunoglobulin-like lectin G) promotes the interaction of the E3 ligase c-Cbl with RIG-I, which mediates its K48-linked ubiquitination in lysine 813 ([@B10]).

MAVS Ubiquitination {#S4.SS2}
-------------------

Mitochondrial antiviral signaling is a direct target of both non-degradative and degradative ubiquitination in the course of antiviral response ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

The E3 ligase TRIM31 has been identified as a regulator of MAVS aggregation via ubiquitination. During viral infection, TRIM31 is recruited to mitochondria, where it catalyzes K63-linked polyubiquitination of MAVS at lysine residues 10, 311, and 461 to facilitate the formation of prion-like aggregates ([@B57]). Interestingly, K63-linked ubiquitination of MAVS has been reported to be stimulated by O-GlcNAcylation, highlighting an unappreciated role of glucose metabolism in host innate immune ([@B54]; [@B94]). In detail, LC-MS/MS analysis identified serine 366 as the residue of MAVS where uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc) is linked by the O-GlcNAc transferase. Moreover, metabolomic analysis of viral infected macrophages revealed an increase of intermediate metabolites involved in hexosamine biosynthesis, the pathway responsible for the generation of UDP-GlcNAc. The functional relationship between RLRs and glucose metabolism was confirmed by the observation that lactate, the end product of glycolysis in anaerobic conditions, acts a negative regulator of MAVS signaling by preventing RIG-I--MAVS complex formation ([@B136]). Interestingly, using a metabolomic approach, it was shown that RLR activation is accompanied by a decrease of glycolysis intermediates, including lactate, which facilitates MAVS-dependent production of type I IFN ([@B136]). In line with these findings, inhibition of mitochondrial oxidative phosphorylation results in an impairment of MAVS-mediated induction of IFNs and inflammatory cytokines, further highlighting how antiviral response and mitochondria metabolism are strictly coordinated ([@B133]).

Non-degradative ubiquitination also favors the interaction of MAVS with downstream effectors. For example, viral infection induces the expression of the E3 ligase TRIM21, which binds MAVS to promote its K27-linked polyubiquitination at lysine 325 and its association with TBK1 ([@B126]). Moreover, TRIM proteins regulate the recruitment of IKKγ/NEMO to MAVS signalosome through their own ubiquitination. For example, upon viral infection, TRIM14 undergoes K63-linked polyubiquitination, which provides a platform for the binding of IKKγ/NEMO to MAVS on OMM ([@B142]). The temporal kinetics of MAVS oligomerization is controlled by either DUBs or proteins containing UBL domains. YOD1, a deubiquitinase of the ovarian tumor family, is an MAVS interactor identified by coIP/MS that translocates to mitochondria upon viral infection to limit its activation through K63-linked deubiquitination ([@B58]). UBXN1 and FAF1, two proteins that contain ubiquitin-associated (UBA) or UBL domains, act as steric antagonists of MAVS. The UBA domain of UBXN1 competes with the TRAF3/6-binding sites of MAVS and interferes with its oligomerization ([@B114]). FAF1 forms aggregates through its UBL domain that negatively regulates MAVS by disrupting its association with TRIM31 ([@B19]).

K48-linked polyubiquitination represents a main mechanism to negatively regulate MAVS signaling by promoting its proteasomal degradation. Lysine 7 was identified as a K48-linked polyubiquitination site on MAVS in a high-resolution proteomic study aimed at investigating endogenous ubiquitination sites through the immuno-enrichment of the di-glycine-lysine remnants that are generated following tryptic digestion of ubiquitinated peptides ([@B111]). More recently, it was shown that the mitochondrial E3 ligase MARCH5 binds to MAVS aggregates during viral infection and conjugates K48-linked polyubiquitin chains at lysine residues 7 and 500, leading to their proteasomal degradation ([@B131]). Proteasomal degradation of MAVS is also triggered by: (i) the tumor suppressor E3 ligase VHL/Cullin 2 ([@B21]), which promotes K48-linked polyubiquitination at lysine 420 residue, (ii) TRIM29, which mediates K11-linked polyubiquitination at lysine residues 371, 420, and 500 ([@B124]), and (iii) ITCH/AIP4, which targets lysine residues 371 and 420 with K48-linked polyubiquitination ([@B134]). In this regard, yeast two-hybrid screens identify poly rC binding protein 1 (PCBP1) and PCBP2 as positive regulators of the interaction between ITCH/AIP4 and MAVS, whose levels are increased upon viral infection ([@B134]). A similar role is played by the adaptor protein TAX1BP1, which is also required for promoting ITCH/AIP4-mediated ubiquitination of MAVS ([@B16]). Interestingly, TRIM25, an E3 ligase responsible for K63 ubiquitination of RIG-I, has also been identified as a MAVS binding partner using GeLC-MS/MS (1D SDS PAGE gel followed by LC-MS/MS). In particular, TRIM25 mediates K48-linked ubiquitination of MAVS at lysine residues 7 and 10, suggesting that the same E3 ligase can initially trigger the antiviral response and, later on, be responsible for its termination by inducing MAVS proteasomal degradation ([@B9]). Other E3 ubiquitin ligases that catalyze K48 ubiquitination of MAVS are SMURF1, SMURF2, Ring Finger protein (RNF) 125, and GP78, but the ubiquitination sites have not been determined yet ([@B2]; [@B116]; [@B39]; [@B81]). Degradative ubiquitination is counteracted by DUBs, as shown for ovarian tumor family deubiquitinase 4 (OTUD4), whose expression is increased by IRF3/7 in a positive-feedback loop ([@B65]).

Ubiquitination can also trigger the autophagic degradation of MAVS. The E3 ubiquitin RNF34 promotes K27/K29-linked polyubiquitination on MAVS at lysine residues 297, 311, 348, and 362. Ubiquitinated MAVS-enriched mitochondria are then recognized by the autophagy receptor NDP52 and delivered to autophagosomes for degradation ([@B33]). Similarly, the IFN-induced Tetherin (also known as BST2) recruits the E3 ligase MARCH8 to mediate K27-linked ubiquitination of MAVS at lysine 7 and subsequent NDP52-dependent autophagic degradation, which is important to prevent excessive activation of RLR signaling ([@B41]).

RIG-I/MDA5 Phosphorylation {#S4.SS3}
--------------------------

Protein phosphorylation is a second main type of PTM that controls MAVS signaling during viral infection ([Figure 2](#F2){ref-type="fig"}). This regulation is important to modulate both the binding of RIG-I/MDA5 to MAVS and the recruitment of downstream effectors to assemble the MAVS signalosome ([@B79]).

On one hand, tyrosine kinases of the SRC family have been shown to stimulate RIG-I activity. CoIP/MS analyses identified LYN as a binding partner of both RIG-I and MAVS in macrophages upon treatment with synthetic analogs of double-stranded RNA ([@B55]). In this condition, LYN phosphorylates RIG-I at tyrosine 396 and promotes its oligomerization. c-SRC was also observed to stimulate RIG-I, but it acts in an indirect manner ([@B51]). In fact, c-SRC phosphorylates TRIM25 at tyrosine 278, thus stimulating K63-linked ubiquitination and oligomerization of RIG-I.

On the other hand, RIG-I/MDA5 phosphorylation in serine and threonine is mainly associated to the inhibition of their activity in resting conditions. The negative roles of this type of phosphorylation were highlighted by an LC-MS/MS analysis of phosphorylated peptides differentially present in ubiquitinated and non-ubiquitinated RIG-I. This study identified, among others, serine 8 and threonine 170 as phosphorylated sites that negatively regulate the ubiquitination on lysine 172 by preventing the binding of TRIM25 ([@B25]; [@B75]). These amino acids are phosphorylated by protein kinase C-α (PKC-α) and PKC-β ([@B67]). Inhibitory phosphorylations were also identified at threonine 770, serine 854, and serine 855 at the C-term domain RIG-I, residues that are phosphorylated by casein kinase II (CK2), and at serine 828 of MDA5, which is carried out by RIO kinase 3 (RIOK3) ([@B99]; [@B102]). In both cases, phosphorylation prevents the oligomerization of these sensor proteins.

Early during viral infection, serine/threonine phosphorylation levels of RIG-I/MDA5 are decreased by PP1α and PP1γ, two protein phosphatases that have been identified through a phosphatome RNAi screen ([@B119]). A combination of RNA interference, yeast two-hybrid, and APEX2 proximity labeling-based MS approaches also identified PPP6C as a phosphatase that controls RIG-I activity. In particular, PPP6C forms a complex with WHIP and TRIM14, which mediate the binding of PPP6C to ubiquitinated RIG-I and MAVS, respectively ([@B104]). At later stages of infection, the inhibitory phosphorylations are re-established and contribute to turning off MAVS signaling. This event is regulated by death associated protein kinase 1 (DAPK1), whose activation is triggered by RIG-I signaling as a negative-feedback mechanism ([@B120]).

MAVS Phosphorylation {#S4.SS4}
--------------------

Various phosphorylations of MAVS have also been characterized with either positive or negative effects on its function ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

Stimulatory phosphorylations were identified by LC-MS/MS analyses at serine residues 442, 444, and 44 in the C terminus of MAVS, which are phosphorylated by TBK1 and IKKβ upon viral infection. This modification is needed to recruit IRF3 on MAVS signalosome and facilitate its phosphorylation by TBK1 ([@B61]). Phosphorylation-driven formation of MAVS signaling complex is countered by PPM1A (protein phosphatase magnesium-dependent 1A, also known as PP2Cα), which targets both MAVS and TBK1/IKKε for dephosphorylation ([@B123]).

c-ABL has been reported to phosphorylate MAVS at tyrosine 9, promoting the formation of MAVS/TRAF3/TRAF6 complex and the activation of the antiviral response ([@B93]). Recently, the role of c-ABL-mediated phosphorylation of MAVS has been further investigated in the context of microglia inflammation, where this kinase promotes MAVS activity by disrupting its interaction with the autophagosome protein LC3 and preventing autophagy-mediated MAVS degradation ([@B12]). Additional activating phosphorylations of MAVS have been identified by proteomic approaches, but the molecular mechanism underlying their effect remains to be elucidated. For example, a quantitative analysis of phospho-peptides using iTRAQ labeling identified serine residues 328 and 330 in mouse MAVS sequence as required for the stimulation of IRF3 and NF-κB activity ([@B43]).

Conversely, phosphorylation of threonine 234 and serine 233 of MAVS was shown to inhibit the antiviral response by serving as a docking site for the recruitment of mitotic kinase Polo-like kinase 1 (PLK1). The PLK1--MAVS interaction, identified through a yeast two-hybrid screen, interferes with the binding of MAVS with TRAF3 and attenuates IFN signaling during viral infection as well as during the G2/M phase of the cell cycle ([@B110]). Recently, an LC-MS/MS study showed that MAVS phosphorylation could also prime MAVS for proteasomal degradation. This is mediated by the NEMO-like kinase (NLK), which targets MAVS at serine residues 121, 212, 258, and 329 ([@B52]).

RIG-I Acetylation {#S4.SS5}
-----------------

A third type of PTM that has been shown to regulate MAVS signaling is protein acetylation. LC-MS/MS analysis identified lysine residues 858 and 909 as acetylated residues of RIG-I that contribute to preventing its oligomerization in resting conditions. The acetyltransferases responsible for this PTM remain to be characterized, while HDAC6 was identified as the deacetylase required for removal of these acetyl groups during viral infection to allow RIG-I activation ([@B15]; [@B59]).

Regulation of MAVS Signaling by Protein--Protein Interaction {#S5}
============================================================

Cellular Protein Interactions {#S5.SS1}
-----------------------------

In addition to PTMs, proteomic analyses have provided a large set of information on how MAVS signaling is regulated by direct protein--protein interactions with cellular and viral factors ([Figure 3](#F3){ref-type="fig"}). Interactomics studies were carried out using either antibody-based affinity pull-down combined with MS analyses, which allows the characterization of protein complexes in a physiological context but favoring stable associations, or yeast two-hybrid assays, which also detect transient or labile interactions but assessed in non-physiological cell systems ([@B68]).

![Regulation of RLR--MAVS signaling by protein--protein interaction. **(A)** RIG-I/MDA5 interaction with MAVS is facilitated by DDX60 and inhibited by NLRX1, ATG5/ATG12 complex, and COX5B (upper panel). ISG15 association to RIG-I promotes leucine-rich repeat containing protein 25 (LRRC25) interaction and p62-mediated autophagic degradation of RIG-I, which is inhibited by LRCC59 (lower panel). **(B)** Mitochondrial fusion and oxidative phosphorylation (OXPHOS) are required for efficient MAVS signaling. In particular, MFN1 and PHB1 and PHB2 act as positive regulators of MAVS signaling, while MFN2, lactate, and NLRX1 negatively regulate MAVS activity. **(C)** Interferon Induced Protein With Tetratricopeptide Repeats 3 (IFIT3) and TOM70 interact with MAVS and function as a scaffold for the recruitment of downstream effectors; protein kinase R (PKR), UBXN1, and LRPPRC interact with MAVS, inhibiting TRAF association (upper and middle panels); LC3--MAVS interaction promotes mitochondrial degradation by mitophagy (lower panels).](fcell-08-00008-g003){#F3}

Various studies have reported that ISGs that are induced upon MAVS activation may establish a positive-feedback loop to potentiate the antiviral signaling at multiple steps ([@B17]). For example, the ISG protein DDX60 is an RNA helicase that, upon binding with double-strand RNA, associates with RIG-I, MDA5, and LGP2, and increases MAVS activation ([@B70]). The shorter isoform of zinc-finger antiviral protein (S-ZAP) is an ISG that associates with RIG-I to promote its oligomerization and activity ([@B30]). Interferon Induced Protein With Tetratricopeptide Repeats 3 (IFIT3) localizes to mitochondria, where it functions as a scaffold to facilitate the interaction of MAVS with TBK1 ([@B63]). The dsRNA-dependent protein kinase R (PKR) is upregulated by type I and type III IFNs and induces MAVS signaling by interacting with TRAF2 and TRAF6 to promote NF-κB activation ([@B26]).

The cytoskeletal network is another source of proteins that were found to stimulate the antiviral response by interacting with components of MAVS signaling. Focal adhesion kinase (FAK) is an actin-associated tyrosine kinase that binds to MAVS in a viral infection-dependent manner and potentiates its signaling independently of its kinase activity ([@B4]). Two microtubule proteins, Rho guanine nucleotide exchange factor 2 (GEF-H1) and HAUS augmin-like complex subunit 8 (HAUS8), also act as positive regulators of the RLR pathway by stimulating TBK1 activity and MAVS ubiquitination, respectively ([@B13]; [@B32]).

A recent study in which global RNA interference analyses were combined to experimentally and computationally derive interactome data has provided an in-depth view of the RIG-I protein interaction network and identified new processes that influence the host response to viral RNA, including the unfolded protein response, WNT/β-catenin signaling, and RNA metabolism. The role of K-Homology Splicing Regulatory Protein (KHSRP), one of the best hits obtained from this screening, was further characterized, showing that its interaction with RIG-I is required to maintain the receptor in an inactive state in resting conditions ([@B95]).

The mitochondrial resident factors NLRX1, LRPPRC, MFN1, MFN2, TOM70, PHB1/2, and LONP1 have been described to interact with MAVS and regulate the antiviral signaling.

NLRX1 (nucleotide-binding domain and leucine-rich repeat containing family member) was the first mitochondrial protein identified as a negative regulator of MAVS ([@B1]). NLRX1 interacts with MAVS via its CARD and interferes with the binding of MAVS with the upstream partners RIG-I and MDA5. However, the role of NLRX1 in MAVS signaling has long been debated. NLRX1-deficient mice exhibit unaltered antiviral and inflammatory responses to Sendai virus, influenza A virus, or synthetic analogs of double-stranded RNA injection when compared to wild-type mice ([@B85]; [@B92]). In addition, NLRX1 may also play a positive role in innate immune signaling mediated by NF-κB through the generation of ROS, which is supported by the observations that NLRX1 is mainly localized to the mitochondrial matrix and interacts with UQCRC2, a protein of the respiratory chain complex III ([@B3]). More recently, the mechanism by which NLRX1 negatively regulates the antiviral response has been refined by studying hepatitis C virus (HCV) infection. In this context, NLRX1 functions as a bridging protein between MAVS and PCBP2, thus promoting the ITCH/AIP4-mediated K48-linked polyubiquitination and degradation of MAVS ([@B84]).

LRPPRC, a protein known to regulate mitochondrial RNA stability, has been characterized as a negative regulator of the mitochondrial-mediated antiviral immunity during HCV infection. In particular, LRPPRC interacts with MAVS and inhibits its signaling by preventing the association with TRAF3 and TRAF6 ([@B86]).

The mitochondrial fusion protein MFN2 has been identified as a negative regulator of MAVS-mediated antiviral signaling through an LC-MS/MS-based interactome analysis. MFN2 binds to MAVS, preventing its oligomerization and the propagation of the downstream antiviral response ([@B128]). This MFN2 function is distinct from its role in mitochondrial dynamics. In fact, the inhibition of mitochondrial fusion by the concomitant downregulation of MFN1 and MFN2 expression ([@B47]), as well as that of OPA1 ([@B133]), leads to the repression of MAVS activity, which is associated to a dissipation of mitochondrial membrane potential. Moreover, MFN1 was shown to physically interact with MAVS and promote RIG-I-mediated MAVS oligomerization, suggesting also a direct involvement of MFN1 in the induction of the mitochondrial antiviral response ([@B78]).

Analysis of MAVS interacting proteins upon mitochondrial enrichment and GeLC-MS/MS identified the mitochondrial protein TOM70 (translocase of outer membrane 70) as a novel component of the MAVS signalosome. In detail, Tom70 acts as a promoting factor of the antiviral response by functioning as a scaffold for the recruitment of both IRF3 and TBK1, in association with HSP90, to MAVS ([@B64]).

A positive role of the inner mitochondrial membrane (IMM) proteins PROHIBITIN 1 (PHB1) and PHB2 in MAVS signaling has recently emerged in a proteomic study aimed at characterizing the function of the coiled coil domains of these mitochondrial scaffold proteins. Upon viral infection, PHBs were shown to form a complex with MAVS oligomers, which also includes the AAA(+) ATPase proteins Caseinolytic Peptidase B (CLPB) Homolog and ATPase Family AAA Domain Containing 3A (ATAD3A), thus establishing a bridge between the OMM and IMM that is required for the efficient activation of the RIG-I signaling pathway ([@B132]).

The mitochondrial protease LONP1 has been identified as a positive regulator of MAVS in a coIP/MS-based analysis from purified MAM, a study that was performed using surfactants hydrolyzable at low pH to reduce detergent interference in MS ([@B36]). However, the molecular mechanism underlying this regulation remains to be characterized.

Mitochondrial antiviral signaling activity is also regulated by autophagy through protein--protein interaction. MAVS directly binds to the autophagosome protein LC3 through an LC3-interaction region (LIR) at the MAVS N-terminal region. Through this interaction, MAVS was reported to function as a mitophagy receptor for the engulfment of mitochondria that are damaged upon excessive activation of antiviral signaling ([@B98]). Moreover, the autophagy proteins ATG5--ATG12 were found to downregulate RIG-I signaling by interacting with the CARDs of both RIG-I and MAVS ([@B42]). Interestingly, the mitochondrial protein COX5B has been shown to act in concert with ATG5 in the suppression of MAVS activity both through direct protein interaction and, indirectly, by decreasing ROS levels ([@B139]).

The identification of gC1qR (receptor for globular head domain of complement component C1q) and Sorting nexin 8 (SNX8) as MAVS interacting proteins that regulate the antiviral response suggests a role of other signaling pathways to MAVS activity that remain to be contextualized ([@B125]; [@B28]).

Viral Protein Interactions {#S5.SS2}
--------------------------

Viruses have evolved different mechanisms to inhibit MAVS activity as part of their immune evasion strategies. Viral proteins are able to interfere with the binding of MAVS to the upstream RLR sensors. The non-structural protein NS4A of Dengue and Zika viruses binds to the CARD of MAVS, preventing RIG-I/MDA5 accessibility and hampering RLR signal transduction ([@B34]; [@B66]). Zika NS3 also contributes to the inhibition of MAVS activation, as demonstrated in an interactome study where NS3 was found to bind and inhibit the function of 14-3-3ε, a docking protein required for the translocation of RIG-I/MDA5 to mitochondria ([@B87]).

We have recently characterized the interactome of HCV NS5A using an HCV replicon cell system in which a double tag was inserted in the viral genome in a region of NS5A that did not alter its ability to support viral replication. NS5A coIP was carried out using *n*-dodecyl β-[D]{.smallcaps}-maltoside as a detergent to preserve the integrity of mitochondrial membrane complexes. We found that HCV NS5A interacts with the mitochondrial protein LRPPRC and represses the antiviral response by promoting LRPPRC association with MAVS, which results in a reduced association of MAVS with TRAF proteins ([@B86]).

A peculiar mechanism to elude MAVS activity has been described for human immunodeficiency virus 1 (HIV-1) in dendritic cells. In these cells, the RNA helicase DDX3 acts as an intracellular sensor of abortive HIV-1 RNAs that stimulates MAVS activity by promoting its interaction with TRAF3. HIV-1 is able to block this pathway through the HIV-1 envelope protein GP120, which, by binding to the C-type lectin receptor DC-SIGN, activates PLK1 to interfere with the formation of MAVS--TRAF3 complex ([@B27]).

Finally, a large series of viral proteases induces the proteolytic cleavage of MAVS to release it from the outer membrane of mitochondria. These include: HCV NS3/4A viral protease, which cleaves MAVS at cysteine 508 ([@B53]); hepatitis A virus (HAV) 3ABC precursor of 3Cpro cysteine protease ([@B127]); 3Cpro cysteine protease of coxsackievirus B3 (CVB3), which cleaves MAVS at Q148 within the proline-rich region ([@B73]); and enterovirus 71 (EV71) 2A protease (2Apro), which cleaves MAVS on multiple residues, at Gly209, Gly251, and Gly265 ([@B112]). A different inhibitory mechanism has been described for the influenza A virus PB1-F2 protein and the human cytomegalovirus (HCMV) glycoprotein US9, which interact with MAVS and inhibit its activity by dissipating the mitochondrial membrane potential ([@B107]; [@B14]).

Concluding Remarks {#S6}
==================

The mitochondrial proteome is a highly dynamic entity that undergoes profound changes in response to a variety of stress conditions in the attempt to mount an adaptive response or, when not feasible, to trigger programmed cell death. In this review, we discussed recent findings describing how the host cell response to RNA virus infection is centered on the mitochondrial outer membrane. In this subcellular compartment, MAVS signalosome is rapidly assembled to recruit key components of IRFs and NF-κB signaling pathways and induces the expression of hundreds of genes with antiviral properties. In particular, we highlighted how proteomic approaches have contributed to the characterization of protein networks and their PTMs that regulate MAVS signaling. In addition, for its unbiased characteristics, proteomics has provided several new insights on the crosstalk of the mitochondrial antiviral response with other PPRs, such as NLR and lectins, or other cellular processes, such as glucose metabolism. The key contribution of proteomic studies to unraveling the complexity of the antiviral response is expected to have an important impact on the development of novel therapeutic strategies aimed at suppressing viral infection and enhancing immune responses.

Author Contributions {#S7}
====================

GR, GF, and FC wrote the text and prepared the figures. TV and MP contributed to literature search and revised the manuscript and discussion.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported in part by grants from AIRC (IG2015 n. 17404 to GF and IG2014 n. 15244 to MP), the Italian Ministry of University and Research (FIRB Accordi di Programma 2011 to MP and PRIN 2015 20152CB22L to GF), the Italian Ministry of Health (Ricerca Corrente to MP and GF, Ricerca Finalizzata GR-2013-02359524 to TV), Fondazione Fibrosi Cistica (Progetto FFC\#8/2018 to MP), Regione Lazio (Progetto "Gruppi di Ricerca" 2018 to MP), and Transautophagy COST action CA15138 to GF.

[^1]: Edited by: Luisa Pieroni, Santa Lucia Foundation (IRCCS), Italy

[^2]: Reviewed by: Takumi Koshiba, Kyushu University, Japan; Mitsutoshi Yoneyama, Chiba University, Japan

[^3]: This article was submitted to Cell Death and Survival, a section of the journal Frontiers in Cell and Developmental Biology
